Guides urgent blood pressure management with target reduction rates and IV medication protocols. Use when managing hypertensive crises, selecting IV antihypertensives, or monitoring acute BP reduction.
Guides urgent blood pressure management with target reduction rates and IV medication protocols.
Hypertensive emergencies — defined as severely elevated BP (often > 180/120 mmHg) with acute end-organ damage — carry mortality rates of 1–2% per hour if untreated. The distinction between hypertensive emergency (end-organ damage present) and hypertensive urgency (elevated BP without acute damage) is critical, as management strategies differ fundamentally: emergencies require IV therapy with controlled rate of BP reduction, while urgencies can be managed with oral agents.
The 2017 ACC/AHA Hypertension Guideline and critical care consensus documents define target reduction rates specific to each end-organ presentation. Overly rapid BP reduction risks watershed infarction, especially in patients with chronic hypertension whose autoregulatory curve is right-shifted.
Hypertensive Emergency (requires IV therapy, ICU monitoring):
| End-Organ Target | Presentation | Key Diagnostics |
|---|---|---|
| Brain — hypertensive encephalopathy | Headache, confusion, visual changes, seizures, papilledema | CT/MRI head; fundoscopy |
| Brain — ischemic stroke | Focal neurologic deficits | CT head; CTA |
| Brain — hemorrhagic stroke/SAH | Thunderclap headache, neurologic deficits | CT head |
| Heart — acute HF/pulmonary edema | Dyspnea, rales, S3, JVD | CXR, BNP, echo |
| Heart — ACS | Chest pain, ECG changes, troponin elevation | ECG, troponins |
| Aorta — acute dissection | Tearing chest/back pain, BP differential between arms | CTA aorta |
| Kidney — acute renal injury | Oliguria, rising Cr, hematuria, proteinuria | BMP, UA with microscopy |
| Blood — TMA/MAHA | Schistocytes, thrombocytopenia, elevated LDH | CBC, smear, LDH, haptoglobin |
| Pregnancy — eclampsia/preeclampsia | Seizures, proteinuria, elevated LFTs, thrombocytopenia | Labs, urine protein, fetal monitoring |
Hypertensive Urgency (no end-organ damage):
General Principle: Reduce MAP by no more than 25% in the first hour, then to 160/100 over the next 2–6 hours, then gradually to normal over 24–48 hours.
Presentation-Specific Targets:
| Presentation | First-Hour Target | 2–6 Hour Target | Agent of Choice |
|---|---|---|---|
| Hypertensive encephalopathy | Reduce MAP by 20–25% | 160/100 | Nicardipine or labetalol |
| Acute ischemic stroke (no tPA) | < 220/120 (permissive) | Maintain < 220/120 | Labetalol or nicardipine |
| Acute ischemic stroke (tPA eligible) | < 185/110 pre-tPA; < 180/105 post-tPA | Maintain target | Labetalol or nicardipine |
| Hemorrhagic stroke | SBP < 140 (INTERACT2/ATACH-2) | Maintain < 140 | Nicardipine or clevidipine |
| Aortic dissection | SBP < 120 AND HR < 60 within 20 min | Maintain target | Esmolol + nicardipine (BB first to prevent reflex tachycardia) |
| Acute pulmonary edema | Reduce MAP by 25% | Afterload reduction | Nitroglycerin or nitroprusside + furosemide |
| ACS | Reduce to relieve ischemia | Titrate to symptoms | Nitroglycerin, esmolol |
| Eclampsia/preeclampsia | SBP < 160, DBP < 110 | Maintain target | IV labetalol or IV hydralazine; magnesium for seizure prophylaxis |
| Pheochromocytoma crisis | Reduce BP gradually | Titrate to symptoms | Phentolamine (alpha-blocker first; never BB alone) |
First-Line IV Agents:
| Agent | Mechanism | Dose | Onset | Notes |
|---|---|---|---|---|
| Nicardipine | DHP CCB | 5–15 mg/hr IV infusion | 5–15 min | Preferred in most emergencies; titratable |
| Labetalol | Combined α/β-blocker | 20 mg IV bolus, then 0.5–2 mg/min infusion | 5–10 min | Avoid in acute HF, asthma, cocaine |
| Esmolol | β1-selective | 500 mcg/kg bolus → 50–200 mcg/kg/min | 1–2 min | Ultra-short acting; ideal for dissection |
| Clevidipine | DHP CCB | 1–2 mg/hr → titrate by doubling q90s (max 32 mg/hr) | 2–3 min | Ultra-short acting; lipid-based emulsion |
| Nitroglycerin | Venodilator | 5–200 mcg/min | 2–5 min | Best for ACS, pulmonary edema |
| Nitroprusside | Arterial + venous dilator | 0.25–10 mcg/kg/min | Immediate | Cyanide toxicity risk > 48 hours; avoid in renal failure |
| Fenoldopam | D1-agonist | 0.1–1.6 mcg/kg/min | 5–15 min | Renal protective; avoid with glaucoma |
| Hydralazine | Direct vasodilator | 10–20 mg IV q4–6h | 10–20 min | Unpredictable; use in eclampsia when labetalol unavailable |
| Phentolamine | Alpha-blocker | 5–15 mg IV bolus | 1–2 min | Pheochromocytoma/catecholamine excess only |
ICU Monitoring Requirements:
Titration Rules:
Oral Agent Selection (overlap with IV for 4–6 hours before discontinuing IV):
| Agent | Dose | Notes |
|---|---|---|
| Amlodipine | 5–10 mg daily | Long-acting CCB; good for nicardipine bridge |
| Lisinopril/Enalapril | 5–20 mg daily | ACEi; avoid in AKI, bilateral RAS, pregnancy |
| Losartan/Valsartan | 25–160 mg daily | ARB alternative to ACEi |
| Labetalol PO | 100–400 mg BID | Bridge from IV labetalol |
| Metoprolol | 25–200 mg daily | Alternative beta-blocker |
| Clonidine | 0.1–0.3 mg BID | Useful for medication non-adherence; risk of rebound |
Discharge Planning: